O Orstavik1, S H Ata, J Riise, C P Dahl, G Ø Andersen, F O Levy, T Skomedal, J-B Osnes, E Qvigstad. 1. Department of Pharmacology, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; K.G. Jebsen Cardiac Research Centre, Faculty of Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND AND PURPOSE: Levosimendan is known as a calcium sensitizer, although it is also known to inhibit PDE3. We aimed to isolate each component and estimate their contribution to the increased cardiac contractility induced by levosimendan. EXPERIMENTAL APPROACH: Contractile force was measured in electrically stimulated ventricular strips from explanted failing human hearts and left ventricular strips from normal male Wistar rats. PDE activity was measured in a two-step PDE activity assay on failing human ventricle. KEY RESULTS: Levosimendan exerted a positive inotropic effect (PIE) reaching maximum at 10(-5) M in ventricular strips from failing human hearts. In the presence of the selective PDE3 inhibitor cilostamide, the PIE of levosimendan was abolished. During treatment with a PDE4 inhibitor and a supra-threshold concentration of isoprenaline, levosimendan generated an amplified inotropic response. This effect was reversed by β-adrenoceptor blockade and undetectable in strips pretreated with cilostamide. Levosimendan (10(-6) M) increased the potency of β-adrenoceptor agonists by 0.5 log units in failing human myocardium, but not in the presence of cilostamide. Every inotropic response to levosimendan was associated with a lusitropic response. Levosimendan did not affect the concentration-response curve to calcium in rat ventricular strips, in contrast to the effects of a known calcium sensitizer, EMD57033 [5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one]. PDE activity assays confirmed that levosimendan inhibited PDE3 as effectively as cilostamide. CONCLUSIONS AND IMPLICATIONS: Our results indicate that the PDE3-inhibitory property of levosimendan was enough to account for its inotropic effect, leaving a minor, if any, effect to a calcium-sensitizing component.
BACKGROUND AND PURPOSE:Levosimendan is known as a calcium sensitizer, although it is also known to inhibit PDE3. We aimed to isolate each component and estimate their contribution to the increased cardiac contractility induced by levosimendan. EXPERIMENTAL APPROACH: Contractile force was measured in electrically stimulated ventricular strips from explanted failing human hearts and left ventricular strips from normal male Wistar rats. PDE activity was measured in a two-step PDE activity assay on failing human ventricle. KEY RESULTS:Levosimendan exerted a positive inotropic effect (PIE) reaching maximum at 10(-5) M in ventricular strips from failing human hearts. In the presence of the selective PDE3 inhibitor cilostamide, the PIE of levosimendan was abolished. During treatment with a PDE4 inhibitor and a supra-threshold concentration of isoprenaline, levosimendan generated an amplified inotropic response. This effect was reversed by β-adrenoceptor blockade and undetectable in strips pretreated with cilostamide. Levosimendan (10(-6) M) increased the potency of β-adrenoceptor agonists by 0.5 log units in failing human myocardium, but not in the presence of cilostamide. Every inotropic response to levosimendan was associated with a lusitropic response. Levosimendan did not affect the concentration-response curve to calcium in rat ventricular strips, in contrast to the effects of a known calcium sensitizer, EMD57033 [5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one]. PDE activity assays confirmed that levosimendan inhibited PDE3 as effectively as cilostamide. CONCLUSIONS AND IMPLICATIONS: Our results indicate that the PDE3-inhibitory property of levosimendan was enough to account for its inotropic effect, leaving a minor, if any, effect to a calcium-sensitizing component.
Authors: V S Moiseyev; P Põder; N Andrejevs; M Y Ruda; A P Golikov; L B Lazebnik; Z D Kobalava; L A Lehtonen; T Laine; M S Nieminen; K I Lie Journal: Eur Heart J Date: 2002-09 Impact factor: 29.983
Authors: F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: Szabolcs Szilágyi; Piero Pollesello; Jouko Levijoki; Petri Kaheinen; Heimo Haikala; István Edes; Zoltán Papp Journal: Eur J Pharmacol Date: 2004-02-13 Impact factor: 4.432
Authors: Christoph Maack; Thomas Eschenhagen; Nazha Hamdani; Frank R Heinzel; Alexander R Lyon; Dietmar J Manstein; Joseph Metzger; Zoltán Papp; Carlo G Tocchetti; M Birhan Yilmaz; Stefan D Anker; Jean-Luc Balligand; Johann Bauersachs; Dirk Brutsaert; Lucie Carrier; Stefan Chlopicki; John G Cleland; Rudolf A de Boer; Alexander Dietl; Rodolphe Fischmeister; Veli-Pekka Harjola; Stephane Heymans; Denise Hilfiker-Kleiner; Johannes Holzmeister; Gilles de Keulenaer; Giuseppe Limongelli; Wolfgang A Linke; Lars H Lund; Josep Masip; Marco Metra; Christian Mueller; Burkert Pieske; Piotr Ponikowski; Arsen Ristić; Frank Ruschitzka; Petar M Seferović; Hadi Skouri; Wolfram H Zimmermann; Alexandre Mebazaa Journal: Eur Heart J Date: 2019-11-21 Impact factor: 29.983
Authors: Mendel Castle-Kirszbaum; Leon Lai; Julian Maingard; Hamed Asadi; R Andrew Danks; Tony Goldschlager; Ronil V Chandra Journal: Neurosurg Rev Date: 2021-03-08 Impact factor: 3.042
Authors: Øivind Ørstavik; Ornella Manfra; Kjetil Wessel Andressen; Geir Øystein Andersen; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert Journal: PLoS One Date: 2015-03-04 Impact factor: 3.240
Authors: Sandra E Pineda-Sanabria; Ian M Robertson; Yin-Biao Sun; Malcolm Irving; Brian D Sykes Journal: J Mol Cell Cardiol Date: 2016-02-04 Impact factor: 5.000